Singh Krishna P, Verma Neeraj, Akhoon Bashir A, Bhatt Vishal, Gupta Shishir K, Gupta Shailendra K, Smita Suchi
Department of Bioinformatics, CSIR-Indian Institute of Toxicology Research, Lucknow, 226001, India.
Society for Biological Research and Rural Development, Kanpur, 208014, India.
3 Biotech. 2016 Jun;6(1):39. doi: 10.1007/s13205-015-0352-z. Epub 2016 Jan 27.
Human papilloma virus (HPV) is the primary etiological agent responsible for cervical cancer in women. Although in total 16 high-risk HPV strains have been identified so far. Currently available commercial vaccines are designed by targeting mainly HPV16 and HPV18 viral strains as these are the most common strains associated with cervical cancer. Because of the high level of antigenic specificity of HPV capsid antigens, the currently available vaccines are not suitable to provide cross-protection from all other high-risk HPV strains. Due to increasing reports of cervical cancer cases from other HPV high-risk strains other than HPV16 and 18, it is crucial to design vaccine that generate reasonable CD8+ T-cell responses for possibly all the high-risk strains. With this aim, we have developed a computational workflow to identify conserved cross-clade CD8+ T-cell HPV vaccine candidates by considering E1, E2, E6 and E7 proteins from all the high-risk HPV strains. We have identified a set of 14 immunogenic conserved peptide fragments that are supposed to provide protection against infection from any of the high-risk HPV strains across globe.
人乳头瘤病毒（HPV）是导致女性宫颈癌的主要病原体。尽管目前已总共鉴定出16种高危HPV毒株。目前可用的商业疫苗主要针对HPV16和HPV18病毒株设计，因为这些是与宫颈癌相关的最常见毒株。由于HPV衣壳抗原的抗原特异性水平很高，目前可用的疫苗不适用于对所有其他高危HPV毒株提供交叉保护。鉴于除HPV16和18之外，其他高危HPV毒株导致的宫颈癌病例报告不断增加，设计能对所有高危毒株产生合理CD8 + T细胞反应的疫苗至关重要。出于这一目的，我们开发了一种计算流程，通过考虑所有高危HPV毒株的E1、E2、E6和E7蛋白来鉴定保守的跨分支CD8 + T细胞HPV疫苗候选物。我们已经鉴定出一组14个具有免疫原性的保守肽片段，这些片段应该能提供针对全球任何高危HPV毒株感染的保护。
